Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Grellier, P.
space
  arrow  Schaison, G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Remission of Polycythemia Vera after Surgical Cure of Acromegaly

right arrow Pascale Grellier, MD; Philippe Chanson, MD; Nicole Casadevall, MD; Sherry Abboud, MD; and Gilbert Schaison, MD

1 March 1996 | Volume 124 Issue 5 | Pages 495-496


Polycythemia can be classified as a secondary or primary disorder. Increased erythropoietin levels associated with decreased oxygen saturation or with release by certain tumors cause secondary polycythemia. Polycythemia vera is a myeloproliferative disease characterized by abnormal clonal proliferation of an early hematopoietic progenitor, which leads to hyperplasia of all myeloid lineage cells [1]. Diagnostic criteria include increased erythrocyte mass associated with either splenomegaly or increased leukocyte and platelet counts. The precise cause of the marked erythroid expansion observed in patients with polycythemia vera has been debated. Recent studies [2-6] have suggested that insulin-like growth factor 1 (IGF-1) may play a role. We recently evaluated a patient who presented with both polycythemia (with in vitro features of polycythemia vera) and acromegaly. Treatment of acromegaly resulted in complete remission of hematologic abnormalities, suggesting a causal relation between growth hormone or IGF-1 and the development of polycythemia.


Case Report
space
up arrowTop
dotCase Report
down arrowDiscussion
down arrowAuthor & Article Info
down arrowReferences

A 42-year-old man who had had splenectomy for spontaneous splenic hematoma in 1976 was first referred to the department of hematology in 1988 for evaluation of polycythemia. His hematologic variables were the following: hemoglobin level, 187 g/L; hematocrit, 0.58; total blood volume, 88 mL/kg body weight (normal value less than 80 mL/kg body weight); erythrocyte mass, 41 mL/kg body weight; and plasma volume, 46 mL/kg body weight. Serum erythropoietin levels (measured by immunoenzyme assay) were barely detectable at 2 U/L (Table 1). The bone marrow aspirate was hypercellular, with a predominance of erythroid and megakaryocytic progenitors. Marrow samples were then tested by using an in vitro colony-forming unit erythroid assay. Under serum and serum-free conditions, marrow cultures showed spontaneous growth of erythroid progenitors in the absence of exogenous erythropoietin. Several features excluded the diagnosis of secondary polycythemia: normal oxygen saturation, no cardiac or hemoglobin abnormalities, no tumor lesions, and no history of smoking. Leukocyte and platelet counts were normal, and polycythemia vera was diagnosed on the basis of spontaneous in vitro growth of erythroid progenitors [7, 8]. The patient then had therapeutic phlebotomies.


View this table:
[in this window]
[in a new window]
 
Table 1. Biological Characteristics of Patient with Acromegaly and Polycythemia Vera before and after Removal of a Growth Hormone-Secreting Adenoma

 

In 1990, the patient was referred to the department of endocrinology for evaluation of acromegaly. His serum growth hormone (throughout a diurnal hourly profile), serum IGF-1, and urinary growth hormone levels were increased (Table 1). Results of assays for other pituitary hormones were normal. An 8-mm intrasellar pituitary growth hormone-secreting adenoma was surgically removed.

Six months after surgery, serum growth hormone levels, IGF-1 levels, and other pituitary functions were normal, and the hematologic abnormalities had resolved (Table 1). Results of in vitro colony assays no longer showed spontaneous colony growth. After a 4-year follow-up, we have seen no evidence of acromegaly or polycythemia.


Discussion
space
up arrowTop
up arrowCase Report
dotDiscussion
down arrowAuthor & Article Info
down arrowReferences

This patient presented with diagnostic features of polycythemia vera, including an increased hematocrit, erythrocyte mass, and total blood volume; marrow hypercellularity; low serum erythropoietin levels; and spontaneous growth of erythroid progenitors. Spontaneous erythroid progenitor growth, a well-accepted hallmark of myeloproliferative diseases, is known to persist regardless of the course or treatment of the disease [7, 8]. In our patient, the curative effect on hematologic variables of removing the growth hormone or IGF-1 stimulus strongly suggests that hypersensitivity of an abnormal progenitor clone to IGF-1 contributed, at least in part, to the development of polycythemia.

In retrospect, some of the hematologic abnormalities could have been caused by underlying acromegaly. In patients with acromegaly, the hemoglobin level and hematocrit are usually normal and the bone marrow is usually normocellular. We did not observe spontaneous growth of colony-forming unit erythroids in marrow cultures from two patients with active acromegaly (unpublished observations). Although most untreated patients with acromegaly have a normal hematocrit, they also have substantially higher plasma volume, erythrocyte mass, and total blood volume than normal persons; these indices return to normal after treatment [9, 10]. In our patient, the return of these variables to normal may simply reflect the correction of growth hormone levels. After therapy, the hematocrit, erythropoietin level, and in vitro growth of erythroid progenitors also returned to normal, suggesting that growth hormone, IGF-1, or both also induced these abnormalities.

Spontaneous erythroid progenitor growth in vitro is specifically observed with polycythemia vera [7, 8] and is caused, at least in part, by low IGF-1 levels in serum or nondelipidated albumins [11]. Polycythemia vera erythroid progenitors are hypersensitive to low IGF-1 levels compared with normal progenitors [2].

In our patient, the findings suggest that high serum levels of growth hormone, IGF-1, or both may have enhanced the proliferation of an abnormal, hypersensitive progenitor clone to IGF-1. The patient will be followed to determine whether a quiescent, abnormal clone has the potential to recur in the absence of excess hormonal stimulation.

Acknowledgments: The authors thank Drs. Lorian and Helal, who referred the patient to the Department of Endocrinology at the Hopital Bicetre.

Dr. Casadevall: Service d'Hematologie, Hopital Raymond Poincare, 104 Boulevard R. Poincare, F-92380, Garches, France. Dr. Abboud: Department of Medicine/Nephrology, University of Texas Health Science Center, 77 Floyd Curl Drive, San Antonio, TX 78248.


Author and Article Information
space
up arrowTop
up arrowCase Report
up arrowDiscussion
dotAuthor & Article Info
down arrowReferences

From the Hopital Bicetre, Kremlin-Bicetre, France; the Hopital Raymond Poincare, Garches, France; and the University of Texas Health Science Center, San Antonio, Texas.
Grant Support: In part by the Veterans Administration Medical Research Service and National Institutes of Health Grant AR42306.
Requests for Reprints: Gilbert Schaison, MD, Service d'Endocrinologie et des Maladies de la Reproduction Hopital Bicetre, 78, rue du General Leclerc, F-94275 Kremlin-Bicetre, France.
Current Author Addresses: Drs. Grellier, Chanson, and Schaison: Service d'Endocrinologie et des Maladies de la Reproduction Hopital Bicetre, 78, rue du General Leclerc, F-94275 Kremlin-Bicetre, France.


References
space
up arrowTop
up arrowCase Report
up arrowDiscussion
up arrowAuthor & Article Info
dotReferences

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med. 1976; 295:913-6.

2. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994; 83:99-112.

3. Claustres M, Chatelain P, Sultan C. Insulin-like growth factor 1 stimulates human erythroid colony formation in vitro. J Clin Endocrinol Metab. 1987; 65:78-82.

4. Kurtz A, Zapf J, Eckardt KU, Clemons G, Froesch ER, Bauer C. Insulin-like growth factor 1 stimulates erythropoiesis in hypophysectomized rats. Proc Natl Acad Sci U S A. 1988; 85:7825-9.

5. Ratajczak MZ, Kuczynsky WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, et al. A reappraisal of the role of insulin-like growth factor 1 in the regulation of human hematopoiesis. J Clin Invest. 1994; 94:320-7.

6. Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor 1, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest. 1994; 94:34-43.

7. Valla D, Casadevall N, Lacombe G, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985; 103:329-34.

8. Lemoine F, Najman A, Baillou C, Stachowiak J, Boffa G, Aegerter P, et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986; 68:996-1002.

9. Strauch G, Lego A, Therain F, Bricaire H. Reversible plasma and red blood cell volumes increase in acromegaly. Acta Endocrinol (Copenh). 1977; 85:465-78.

10. Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 1990; 113:921-5.

11. Congote LF. Extraction of an erythrotropin-like factor from bovine serum albumin (Cohn fraction V). In Vitro Cell Dev Biol. 1987; 23:361-6.


This article has been cited by other articles:


Home page
Toxicol Ind HealthHome page
L. Claxton
A review of conflict of interest, competing interest, and bias for toxicologists
Toxicology and Industrial Health, November 1, 2007; 23(10): 557 - 571.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Eugster
Gigantism
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4379 - 4384.
[Full Text]


Home page
BloodHome page
A. M. Mirza, S. Ezzat, and A. A. Axelrad
Insulin-Like Growth Factor Binding Protein-1 Is Elevated in Patients With Polycythemia Vera and Stimulates Erythroid Burst Formation In Vitro
Blood, March 15, 1997; 89(6): 1862 - 1869.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Grellier, P.
space
  arrow  Schaison, G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online